Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.58 |
| ▸ | EGFR | P00533 | 13/20 | 0.54 |
| ▸ | RET | P07949 | 2/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.52 |
| ▸ | FLT1 | P17948 | 3/20 | 0.52 |
| ▸ | FLT4 | P35916 | 3/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.52 |
| ▸ | TEK | Q02763 | 2/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.52 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.52 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.52 |
| ▸ | PLK4 | O00444 | 1/20 | 0.52 |
| ▸ | CIT | O14578 | 1/20 | 0.52 |
| ▸ | GAK | O14976 | 1/20 | 0.52 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.52 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.52 |
| ▸ | STK10 | O94804 | 1/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13617590 | 0.94 | KDR (0.65) | KDREGFRRETFGFR1FLT1 | |
| SCHEMBL1614506 | 0.84 | KDR (0.75) | KDREGFRRETFGFR1FLT1 | |
| SCHEMBL6461611 | 0.83 | KDR (0.51) | KDREGFRRETFGFR1FLT1 | |
| SCHEMBL1781194 | 0.82 | KDR (0.67) | KDREGFRRETFGFR1FLT1 | |
| SCHEMBL13617346 | 0.82 | KDR (0.61) | KDREGFRRETFGFR1FLT1 | |
| SCHEMBL12604713 | 0.80 | RET (0.63) | KDREGFRRETFGFR1FLT1 | |
| SCHEMBL1781457 | 0.79 | KDR (0.58) | KDREGFRRETFGFR1FLT1 | |
| SCHEMBL2055590 | 0.77 | KDR (0.75) | KDREGFRRETFGFR1FLT1 | |
| SCHEMBL13617552 | 0.75 | KDR (0.75) | KDREGFRRETFGFR1FLT1 | |
| SCHEMBL2136853 | 0.75 | KDR (0.74) | KDREGFRRETFGFR1FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043395-A1 | Combination therapy comprising zd6474 and a taxane | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043395-A1 | Combination therapy comprising zd6474 and a taxane | ZYX, VEGFA, TEK | KDR 4/4885EGFR 192/4885RET 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.